ORG Wealth Partners LLC Takes Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

ORG Wealth Partners LLC acquired a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 9,823 shares of the company’s stock, valued at approximately $113,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of ROIV. Rubric Capital Management LP increased its position in Roivant Sciences by 15.0% during the second quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock worth $243,110,000 after purchasing an additional 3,000,000 shares during the last quarter. Troluce Capital Advisors LLC acquired a new position in Roivant Sciences during the second quarter worth approximately $31,182,000. Principal Financial Group Inc. increased its position in Roivant Sciences by 3,413.9% during the first quarter. Principal Financial Group Inc. now owns 1,274,737 shares of the company’s stock worth $13,436,000 after purchasing an additional 1,238,460 shares during the last quarter. Clearbridge Investments LLC acquired a new position in Roivant Sciences during the first quarter worth approximately $12,962,000. Finally, BlackBarn Capital Partners LP grew its stake in Roivant Sciences by 63.1% during the second quarter. BlackBarn Capital Partners LP now owns 3,100,000 shares of the company’s stock worth $32,767,000 after buying an additional 1,199,406 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Trading Down 0.5 %

ROIV opened at $11.84 on Tuesday. The stock has a market capitalization of $8.75 billion, a PE ratio of 2.34 and a beta of 1.24. The firm’s fifty day moving average price is $11.64 and its 200 day moving average price is $11.18. The company has a debt-to-equity ratio of 0.05, a current ratio of 27.91 and a quick ratio of 27.91. Roivant Sciences Ltd. has a 12-month low of $8.24 and a 12-month high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.33. The firm had revenue of $55.10 million for the quarter, compared to analysts’ expectations of $30.72 million. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The firm’s quarterly revenue was up 155.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.38) earnings per share. As a group, research analysts expect that Roivant Sciences Ltd. will post -1.14 EPS for the current fiscal year.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, CAO Rakhi Kumar sold 250,000 shares of the stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $11.89, for a total transaction of $2,972,500.00. Following the sale, the chief accounting officer now directly owns 209,322 shares of the company’s stock, valued at approximately $2,488,838.58. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Roivant Sciences news, CEO Matthew Gline sold 1,983,257 shares of the stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $11.79, for a total transaction of $23,382,600.03. Following the sale, the chief executive officer now directly owns 17,870,543 shares of the company’s stock, valued at approximately $210,693,701.97. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Rakhi Kumar sold 250,000 shares of the stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $11.89, for a total transaction of $2,972,500.00. Following the completion of the sale, the chief accounting officer now directly owns 209,322 shares in the company, valued at approximately $2,488,838.58. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,477,309 shares of company stock valued at $40,986,184 over the last ninety days. Corporate insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Bank of America boosted their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research note on Wednesday, September 11th. Piper Sandler boosted their price objective on shares of Roivant Sciences from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Finally, HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Thursday, September 19th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $17.39.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.